IBA expands PET tracer production

IBA Molecular has opened production and distribution of zirconium-89 for preclinical and investigational use with PET for distribution five days a week.

The investigational tracer provides a radioactive half-life of just over 78 hours and is comparable in biodistribution and PET imaging counts to a number of other PET tracers including iodine-124, copper-64 and yttrium-86. Its half-life and biodistribution make zirconium-89 an ideal isotope for radiolabeling antibodies, including monoclonal antibodies, as well as antibody fragments for research and development of novel radioimmunotherapies, according to IBA.

Zirconium-89 is the daughter isotope of yttrium-89, which features a gamma photon with an energy of 909 keV. There are no known interactions between zirconium ions and biological functions.

With increased availability of zirconium-89, IBA seeks to expand product development and commercialization services at its New Jersey-based radiolabeling and production facility for biotechnology, pharmaceutical and other research institutions aiming to develop new tracers for potential use in clinical trials.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.